` 603658 (Autobio Diagnostics Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

603658
vs
Shanghai Composite

Over the past 12 months, has underperformed Shanghai Composite, delivering a return of -24% compared to the Shanghai Composite's 12% growth.

Stocks Performance
603658 vs Shanghai Composite

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
603658 vs Shanghai Composite

Loading
603658
Shanghai Composite
Difference

Performance By Year
603658 vs Shanghai Composite

Loading
603658
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Autobio Diagnostics Co Ltd vs Peers

Shanghai Composite
603658
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Autobio Diagnostics Co Ltd
Glance View

Market Cap
24B CNY
Industry
Health Care

Autobio Diagnostics Co., Ltd. is a company that has carved a distinctive niche in the biotechnology landscape, particularly within the realm of in-vitro diagnostics (IVD). The company's journey began with a mission to enhance healthcare by providing advanced diagnostic tools that offer precise and timely results. Specializing in the development, production, and distribution of diagnostic reagents and instruments, Autobio has dedicated itself to innovation and quality in medical diagnostics. Its expansive product portfolio covers areas such as immunoassay detection, microbiology, clinical chemistry, and molecular diagnostics, catering to both hospital laboratories and independent labs. The firm prides itself on adopting cutting-edge technology to create solutions that are not only efficient and cost-effective but also align with global health standards. The financial heartbeat of Autobio lies in its strategic approach to generating revenue through diverse streams. With a keen focus on research and development, the company continually innovates its product lines, thereby sustaining a competitive edge in the fast-evolving diagnostics market. Additionally, its revenue model capitalizes heavily on the consumables-market; reagents and test kits are used in routine diagnostics, creating a recurring income source as these products need constant replenishment. By expanding its geographic footprint through partnerships and direct sales channels, Autobio enhances its market reach, strengthening its ability to leverage scale economies. Moreover, the company’s commitment to maintaining strong customer relationships through robust after-sales service and technical support has built a loyal base, further fueling its revenue engine.

Intrinsic Value
75.56 CNY
Undervaluation 45%
Intrinsic Value
Price
Back to Top